United States

People: Novo Nordisk A/S (NVO)

NVO on New York Consolidated

28 Oct 2016
Change (% chg)

$-5.07 (-12.38%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hewitt, Liz 

Ms. Liz Hewitt has been Independent Member of the Board of Directors of Novo Nordisk A/S since March 21, 2012. She has been Chairman of the Company's Audit Committee since 2015 and Member of the Nomination Committee since April 2013. She was previously Group Director Corporate Affairs for Smith & Nephew plc from 2004 until 2011 and was involved at a senior level in all aspects of the business, including membership of Risk Committee of the company. From 1986 until 2004, she held a number of roles at 3i Group plc, from investing and syndicating private equity transactions to running the internal consultancy team, culminating her role as Director Corporate Affairs, when she was a Member of Risk Committee and a Trustee of the 3i Charitable Foundation. She qualified with Andersen & Co and also worked as a private equity investor for Citicorp Venture Capital (currently CVC) and Gartmore Investment Management Ltd. She serves as Member of the Board and Chair of Audit Committee of Savills plc. She is also Board Member and Chair of Nomination Committee of Melrose Industries plc and External Member of the Audit Committee of the House of Lords, the United Kingdom. She has experience within the field of medical devices, financial knowledge and knowledge of how international companies operate. She holds a Bachelor of Science degree with honors in Economics from University College London from 1977 and became Chartered Accountant FCA from the Institute of Chartered Accountants in 1982.

Basic Compensation

Total Annual Compensation, DKK 1,400,000
Restricted Stock Awards, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 1,400,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --